title: Surgical treatment of hypothalamic hamartoma causing central precocious puberty: long-term follow-up.
abstract: Hypothalamic hamartoma (HH) is a rare condition that often manifests as central precocious puberty (CPP). There is a lack of information available concerning the long-term effectiveness of surgery for the treatment of CPP due to HH. Here the authors describe 3 cases of CPP due to HH, with a follow-up ranging from 9 to 11 years after surgery. Three girls experienced breast growth and menses at 5-18 months of age and 5-36 months of age, respectively. Serum concentrations of luteinizing hormone, follicle-stimulating hormone, and estradiol concentrations ranged from 2.5 to 6.5 mIU/ml, 4.8-5.9 mIU/ml, and 47.9-133.0 pg/ml, respectively. Magnetic resonance imaging confirmed that CPP was caused by HH. Lesions were resected using a right pterional approach. After surgery, endocrine hormone concentrations were normalized, breasts shrunk, and menses ceased in each patient. Moreover, all of them subsequently developed normally and experienced age-appropriate onset of puberty. Each patient's height and weight were normal at the most recent follow-up (9-11 years after surgery), and none had experienced learning difficulties. Central precocious puberty due to HH can be successfully treated with resection. In the 3 cases presented, this approach was associated with both short- and long-term efficacy.
authors.affiliation: Department of Neurosurgery, Beijing Tiantan Hospital, Capital University of Medical Sciences, Beijing, People's Republic of China.
authors.forename: Chun-de
authors.initials: CD
authors.lastname: Li
authors.forename: Shi-qi
authors.initials: SQ
authors.lastname: Luo
authors.forename: Jian
authors.initials: J
authors.lastname: Gong
authors.forename: Zhen-yu
authors.initials: ZY
authors.lastname: Ma
authors.forename: Ge
authors.initials: G
authors.lastname: Jia
authors.forename: Yu-qi
authors.initials: YQ
authors.lastname: Zhang
authors.forename: Jie-fei
authors.initials: JF
authors.lastname: Li
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000627:therapeutic use; D006065:Gonadotropins, Pituitary / Q000097:blood*; D006222:Hamartoma / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007027:Hypothalamic Diseases / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000601:surgery*; D007223:Infant; D007986:Luteinizing Hormone / Q000097:blood; D008279:Magnetic Resonance Imaging; D011629:Puberty, Precocious / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D016634:Radiosurgery; D012741:Sexual Maturation; D016896:Treatment Outcome
chemical_list: D006065:Gonadotropins, Pituitary; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone